Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Cancer Prev Res (Phila). Author manuscript; available in PMC 2017 August 9.
Published in final edited form as:
PMCID: PMC5550020

Predicting Progression of Oral Dysplasia -- Response

We thank Drs Gomes, Fonseca-Silva and Gomez for their comments on our recently published article (1). That paper validated a loss of heterozygosity (LOH) risk model for use in differentiating between high-risk and low-risk oral dysplasias – a critical barrier in selecting patients for advanced oral cancer preventive intervention. We agree with Dr Gomes and colleagues that there is a need to build on this finding and to develop a clinical tool that is accessible to a broad range of users. However, we stress caution in the way in which this evolution in technology occurs and the need to ensure that changes in protocol result in a new technology that has similar (or improved) capacity to predict outcome for such lesions.

The data shown by Dr Gomes et al illustrates some of the inherent difficulties that can occur when making a transition between different platforms as biomarkers evolve. Our protocol used a “radiation-labelling visual inspection” of PCR products separated on polyacrylamide gels. Gomes et al propose the evolution to a “dye-labelling intensity comparison” with samples separated by capillary electrophoresis. It is important to note that the interpretation of data can be subjective in both systems and each will have its own limitations and biases, with experience of the user being important. For example, the primer set used in figure 1A resulted in the two bands differing widely in intensity on polyacrylamide gels; in our opinion, not ideal for gel electrophoresis. It was scored by Gomes et al as negative by visual inspection but we suggest that there appears to be some imbalance in the allele patterns. With an increase in exposure time, the imbalance may become more apparent and be scored as a loss. Figure 1b points to a sample showing somewhat weaker intensity of the upper band compared to the lower band in the gel analysis. This might qualify for LOH if the upper band was better resolved. The authors score this sample as negative for LOH in the capillary electrophoresis system based on deviation from a chosen cutoff value for differences in intensities of the 2 alleles in control and test samples. The choice of cutoff values for different primer sets affects the sensitivity of the gene scan to distinguish low levels of change in LOH. These levels cannot be arbitrarily chosen but need to be set and then validated clinically. The authors also consider capillary electrophoresis to be more sensitive than gel electrophoresis. It is important to consider the possibility that higher sensitivity of detection may not always result in an improvement in prediction of outcome. In this case, increasing sensitivity might detect smaller numbers of cells with LOH rather than a clone (many cells with LOH). The capacity to clonally expand could matter.

There are other possibilities that could be considered as next steps, many of them cutting edge, such as the development of a “single molecule-based” quantitative analysis using next sequencing technologies such as the Ion Torrent Platform which would produce a call out of number of gene copies (2). We suggest that the choice for technological change requires a careful comparative study between platforms to look for similarities and differences in the LOH calls, to determine the relative ability to detect LOH and its clinical relevance. To that end, the procedure used in our paper represents the only system to be validated prospectively for association with oral cancer risk. As such it represents the validated standard by which other systems in the future could be compared for association with outcome. Perhaps such an approach should be accepted to determine the next evolution of a device – much like drug studies are run – with a validated drug shown to affect outcome being used as the comparative arm in trials using new drugs, to determine if outcome is improved.

The best situation would be for the development of such formal studies with new technologies to be collaborative efforts that would lead to a universal tool that would be broadly adopted instead of a divergence into many “tools” without appropriate validation. The latter course, with multiple tools, means losing the ability to directly compare data from different populations and in different settings between labs. The time to develop that universal tool is now, before we lose both the opportunity and the momentum.


No potential conflicts of interest were disclosed.


1. Zhang L, Poh CF, Williams M, Laronde DM, Berean K, Gardner PJ, et al. Loss of heterozygosity (LOH) profiles – validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila) 2012;5:1081–9. [PMC free article] [PubMed]
2. Rusk N. Torrents of sequence. Nat Meth. 2011;8(1):44.